SEAJME: 12 years of Progress

Final farewell editorial--12 years of progress.

I n 12 years, the Journal of Rehabilitation Research and Development (JRRD) has transformed from a small Department of Veterans Affairs (VA) house-organ into a leading international rehabilitation research publication , benefitting Veterans, all persons with disabilities, and those who care for them. At JRRD, we have fully honored U.S. Public Law 729 passed in 1948, which established the origin...

Stroke: 30 years of progress.

In 3 decades, Stroke has evolved from a fledgling publication to the leading journal in the field. Many factors have contributed to this, particularly the succession of outstanding editors in chief. We begin a series on “Stroke: 30 Years of Progress,” wherein each editor recalls the highlights of his tenure, providing a unique view of the past 3 decades (see page 3 for Dr Millikan’s editorial)....

Twenty-five years of progress.

+ Leprosy: Fifty Years of Progress

The first technical issue of the Boletin de la Oficina Sanitaria Panamericana, published in 1922, was dedicated to leprosy. During the intervening SO years considerable progress has been made in understanding the disease, leading to benefit for the patient and more effective control. Movement away from institutionalization and toward ambulatory care for patients plus new and effective treatment...

Infliximab: 12 years of experience

Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are immune-mediated conditions that share an inflammatory mechanism fuelled by excessive cytokines, particularly TNF. Control of inflammation and rapid suppression of cytokines are important in treating these diseases. With this understanding and the corresponding advent of TNF inhibitors, RA patients, AS patie...